Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Multi-center, Randomized, Blind, Placebo-controlled Study to Evaluate Safety,Tolerance and Efficacy of ASC22 Combined With ART in Subjects With Human Immunodeficiency Virus

Next Previous
X
Search
Trial Profile

A Phase II Multi-center, Randomized, Blind, Placebo-controlled Study to Evaluate Safety,Tolerance and Efficacy of ASC22 Combined With ART in Subjects With Human Immunodeficiency Virus

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Envafolimab (Primary) ; Antiretrovirals; Integrase inhibitors
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Ascletis

    • Most Recent Events

    • 21 Feb 2023 Planned End Date changed from 31 Mar 2023 to 6 Dec 2023.
    • 21 Feb 2023 Planned primary completion date changed from 13 Jan 2023 to 6 Dec 2023.
    • 28 Jun 2022 According to an Ascletis media release, Prof. Fu-Sheng Wang is the principal investigator of the study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top